Juno Therapeutics' cell therapy trial is put on hold

04/10/2014 | Forbes

Two patient deaths during a clinical trial of Juno Therapeutics' chimeric antigen receptor therapy have prompted a halt to the initiation of treatment for new patients until changes are made to the study. The deaths were related to cytokine release syndrome. Juno Therapeutics and Memorial Sloan-Kettering Cancer Center are taking steps to prevent future deaths, and the trial could continue in several weeks pending an FDA review.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN